Kornimate/medical-research-clean huggingface dataset:
quantitative glp-1 receptor imaging correlated to ex vivo distribution of in-111-exendin

Conditions: Diabetes Mellitus

Summary: the main goal is to study the correlation of pancreatic uptake of in-111-dtpa-exendin-4 (measured by ex vivo counting) with the beta cell mass determined in the pancreatic specimens obtained after surgery.

in order to fully characterize the highly promising tracer in-111-dtpa-exendin-4 in humans, quantitative spect imaging will be correlated to the ex vivo tracer distribution in patients undergoing pancreatectomy or a whipple procedure. in vivo imaging will be combined with post-pancreatectomy (micro)autoradiography, measurement of in-111-dtpa-exendin-4 concentrations in the pancreas using a gamma counter and morphometric determination of the actual beta cell mass. by this means, the relation between tracer uptake and beta cell mass in non-diabetic patients and t2d patients will be established. these highly relevant data will allow the improvement of the interpretation of clinical quantitative spect data in subsequent studies in patients with t1d and t2d. in addition, high uptake has been observed in the duodenum/pyloric area in patients in an ongoing study. at this point in time, it remains unclear which cells are responsible for this uptake. it would be of great interest to identify the glp-1r positive cells in order to better understand the physiological actions of glp-1 agonists.

Eligibility criteria:
inclusion criteria: * scheduled for partial or complete pancreatectomy or whipple procedure at radboudumc exclusion criteria: * resection that provides insufficient amount of tissue * previous treatment with synthetic exendin (exenatide, byetta®) or dipeptidyl- peptidase iv inhibitors * breast feeding * pregnancy or the wish to become pregnant within 6 months * renal disease * liver disease * age \< 18 years

Keywords: exendin-4 glp-1 receptor imaging spect pancreas surgery quantification
a precision and accuracy study of the codman valve position verification (vpv) system.

Conditions: Hydrocephalus; Normal Pressure Hydrocephalus

Summary: the purpose of this study is to determine the agreement rate between the codman valve position verification (vpv) adjustment outcome (reprogramming) and x-ray verification in order to support an alternative to x-ray confirmation with respect to the valve adjustment process.

patients with hydrocephalus, managed with an implanted codman hakimtm programmable valve (chpv), occasionally visit their physician to have their valve adjusted to a different setting to manage their condition. after the adjustment, an x-ray of the skull is taken to confirm the valve setting. the codman vpv system is designed to facilitate and confirm the adjustment of a chpv. after signing the informed consent, subjects will be enrolled in the study and have their chpv adjusted using the codman vpv system. after the adjustment, an x-ray of the skull will be taken to verify the valve setting. no further follow up visit is needed after the adjustment. this study is expected to enroll about 300 subjects from up to 20 sites in the united states.

Eligibility criteria:
inclusion criteria: * a codman hakim programmable valve (chpv) has been implanted for the management of the subject's hydrocephalus. * the subject has given written informed consent prior to enrolling in the study. * the subject requires adjustment of the codman hakim programmable valve (chpv) for the management of hydrocephalus· * the subject's implanted chpv will be adjusted using the implanted valve mode. exclusion criteria: * the subject's valve is located in the deep lumbar position. * the subject has an open and/or recent wound site in the region of the implanted valve. * the subject has a history of ultrasound gel allergies. * the subject is a prisoner. * the subject has been previously enrolled in this protocol.

Keywords: hydrocephalus codman hakim programmable valve programmable valve shunt system
multi-organ screening recommendations in patients with lynch syndrome

Conditions: Lynch Syndrome

Summary: the purpose of this study is to examine how people with a family history of colon cancer and other related cancers respond to recommendations for cancer screening after genetic counseling. the purpose of your participation would be to help us learn more about whether people with a personal and/or family history of colorectal cancer and other cancers follow cancer screening recommendations.


Eligibility criteria:
inclusion criteria: * a patient will be eligible for enrollment if he/she is self-referred or physician-referred for genetic counseling at memorial sloan-kettering cancer center's (mskcc) clinical genetics service due to a concern about increased risk for colon cancer or; * an individual who presents for genetic counseling at mskcc's clinical genetics service after undergoing genetic testing at an outside institution with a documented mutation in any gene associated with lynch syndrome or; * an individual who in the context of genetic counseling has received stricter colorectal and/or gynecologic screening recommendations than that of the general population regardless of genetic test results. * dna of patients who have been consented to protocol 93-102 ("ascertainment of peripheral blood or saliva samples for genetic epidemiology studies of familial cancers"), who meet the eligibility criteria listed above, will also be eligible for inclusion in this study. exclusion criteria: * patients will be excluded from this study if: he/she has physical, cognitive or psychiatric conditions that interfere with ability to give meaningful informed consent; he/she cannot read, write or communicate in english; he/she is less than 18 years of age; he/she has received a diagnosis of fap.

Keywords: lynch syndrome 04-144
long term safety study of nva237 vs qab149 in copd patients

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of the study is to provide long term safety data of nva237. this study will assess the safety and tolerability of a single dose strength of nva237.


Eligibility criteria:
inclusion criteria: 1. male or female patients with copd according to gold 2011 who have signed informed consent. 2. patients with airflow limitation of 30-80% post-bronchodilator fev1 at run-in. 3. current or ex-smokers with a smoking history of at least 10 pack years 4. patients with a mmrc score of at least 2 at run-in. exclusion criteria: 1. patients contraindicated for muscarinic antagonist agents and beta-2 agonists 2. patients with a history of malignancy of any organ system, treated or untreated, within the last five years 3. patients with narrow-angle glaucoma, bph or bladder-neck obstruction or moderate-severe renal impairment or urinary retention 4. patients who had a copd exacerbation within 6 weeks prior to screening. 5. patients requiring long term oxygen therapy prescribed for more than 12 hr per day. 6. patients with a history of asthma. 7. patients with an onset of respiratory symptoms, including copd diagnosis, prior to 40 years of age. 8. patients with a blood eosinophil count of greater than 600 mm/3 during run-in 9. patients with concomitant pulmonary disease 10. patients with a history of certain cardiovascular co-morbid conditions 11. patients with a diagnosis of alpha-1 anti-trypsin deficiency 12. patients with active pulmonary tuberculosis 13. patients in the active phase of a pulmonary rehabilitation programme 14. other protocol-defined inclusion / exclusion criteria may apply

Keywords: copd, nva237, qab149, glycopyrronium bromide
humoral and cell mediated immunity and safety of mf59c.1-adjuvanted subunit influenza vaccine or a conventional subunit influenza vaccine in previously unvaccinated healthy subjects

Conditions: Seasonal Influenza; Influenza; Influenza Due to Unspecified Influenza Virus; Human Influenza

Summary: this study aims to evaluate the immunogenicity, by means of cell mediated immunity (cmi) and hemagglutination inhibition (hi) assay, and also the safety of a mf59c.1-adjuvanted subunit influenza vaccine compared with a conventional subunit vaccine in previously unvaccinated children aged 6 to \<36 months.


Eligibility criteria:
inclusion criteria: * male and female previously unvaccinated healthy children aged 6 to \<36 months. exclusion criteria: * any known or suspected impairment of the immune system, any serious disease. * any subjects receiving licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study. * individuals who have had influenza vaccine or documented suspected influenza disease prior to day 1.

Keywords: cell mediated immunity cell mediated immune response children adjuvanted
cervical stabilization training on individuals with headache

Conditions: Headache

Summary: headache is a common health problem. the most common headaches worldwide are migraine, tension-type headache (tth), and cervicogenic headache (cgh). due to the close anatomical relationship between the head and the cervical region, neck pain accompanies these headaches. the effects of cervical stabilization training including all of the cervical regions, thoracic regions, and the upper extremities in individuals with headaches are not yet known.

headache is a common health problem. the most common headaches worldwide are migraine, tension-type headache (tth), and cervicogenic headache (cgh). due to the close anatomical relationship between the head and the cervical region, neck pain accompanies these headaches. most of the previous studies examined the effects of exercise programs such as cranio-cervical flexion exercises (ccfe), posture exercises, muscle strengthening, and stretching exercises of the neck and shoulder on headaches. these studies presented the beneficial effects of ccfe which mostly targeted strengthening the superficial neck and shoulder muscles. however, the effects of cervical stabilization training including all of the cervical regions, thoracic regions, and the upper extremities in individuals with headaches are not yet known.

Eligibility criteria:
inclusion criteria: 1. a clinical diagnosis of migraine, tension-type headache (tth), and cervicogenic headache (cgh) 2. age between 18 and 55 years 3. being female 4. frequency of headaches at least once a week or more in the last year exclusion criteria: 1. having a neurological and orthopedic disease such as parkinson's, stroke, cognitive disorders, and temporomandibular joint dysfunction, 2. having any contraindication for exercise, 3. having any serious head and/or neck trauma, 4. being with menopause, 5. being included in a physiotherapy program for head and neck pain in the last 12 months.

Keywords: headache neck pain exercise
a study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in hepatocellular carcinoma previously treated with atezolizumab and bevacizumab

Conditions: Unresectable Hepatocellular Carcinoma

Summary: this is a phase iii, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic hepatocellular carcinoma (hcc) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.


Eligibility criteria:
inclusion criteria: * locally advanced or metastatic and/or unresectable hcc with diagnosis confirmed by histology/ cytology or clinically by american association for the study of liver diseases (aasld) criteria in cirrhotic patients. * disease progression following prior atezolizumab plus bevacizumab combination treatment for hcc, for at least 4 consecutive treatment cycles, and 2 subsequent tumor assessments. it is required that at least 1 tumor assessment shows either stable disease (sd), partial response (pr), or complete response (cr). * at least one measurable (per recist v1.1) target lesion that has not been previously treated with local therapy or, if the target lesion is within the field of previous local therapy, has subsequently progressed in accordance with recist v1.1. * eastern cooperative oncology group performance status (ecog ps) of 0 or 1 within 7 days prior to randomization * child-pugh class a within 7 days prior to randomization * adequate hematologic and end-organ function exclusion criteria: * symptomatic, untreated, or actively progressing central nervous system (cns) metastases. * history of leptomeningeal disease * history of hepatic encephalopathy, preceding 6 months, unresponsive to therapy within 3 days * known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc * history of malignancy other than hcc within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death
a registry of de winter symdrome of single center

Conditions: ACS - Acute Coronary Syndrome

Summary: this registry started january 1,2018 to collect patients who diagnosed as de winter symdrome for the first time in hainan general hospital.all enrolled patients will receive 30 days followed-up.


Eligibility criteria:
inclusion criteria: * index ecg st segment showed a 1- to 3-mm upsloping st-segment depression at the j point in leads v1 to v6 that continued into tall, positive symmetrical t waves * received coronary angiography during hospitalization exclusion criteria: -no coronary angiography results was available during hospitalization

Keywords: de winter syndrome
nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis

Conditions: Bronchiolitis

Summary: the purpose of this study is planned to investigate whether frequently inhaled hypertonic saline (hs) can relieve symptoms and signs faster than normal saline (ns) and shorten length of stay (los) significantly for moderately to severely ill infants with bronchiolitis without apparent adverse effects.

the treatment of bronchiolitis remains largely supportive with mechanical ventilatory support as needed .other types of treatment remain controversial.we and other researchers have demonstrated that nebulized hs and bronchodilators decreased symptoms and los for infants with mild to moderate viral bronchiolitis .all the aforementioned studies used 3 times per day dosing, which is significantly less than the 3 to 6 times per hour regimens often used in children in respiratory distress.frequently nebulized hs reduced the los for infants with moderately severe bronchiolitis.the present study is planned to investigate whether frequently inhaled hs can relieve symptoms and signs faster than ns and shorten los significantly for moderately to severely ill infants with bronchiolitis without apparent adverse effects. pmid: 15266547 pmid: 12576370 pmid: 16599051 pmid: 17719935 pmid: 20014350 pmid: 12475841

Eligibility criteria:
inclusion criteria: * infants less than 24 months of age with first episode of wheezing. exclusion criteria: * age\>24 months, * previous episode of wheezing, * chronic cardiac and pulmonary disease, * immunodeficiency, * accompanying respiratory failure, * requiring mechanical ventilation, * inhaling the nebulized 3% hypertonic saline solution 12 hours before treatment, * premature infants born at less than 34 weeks gestation.

Keywords: hypertonic saline solution, bronchiolitis, rsv
vestibular stimulation therapy for rhythmic movement disorder

Conditions: Sleep Related Rhythmic Movement Disorder (Disorder)

Summary: this study aims to a) investigate the feasibility of the detection of episodes of rmd using contactless 3d video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.

rhythmic movement disorder (rmd) is a childhood onset sleep disorder that is characterised by repetitive movements that involve large muscle groups, such as body rocking, rolling and head banging. these rhythmic movements are performed prior to and during sleep and as such can disturb sleep with clinical consequences. there is no standard measure to quantify the severity of rhythmic movements. 3d video offers a contactless method of achieving this without disrupting the child's sleep. vestibular stimulation has a soothing effect and might be effective in promoting sleep. furthermore, mild vestibular stimulation in the form of gentle rocking movements generated by the somnomat device might function as a stimulation substitute for the child's rmd with therapeutic potential. this study aims to a) investigate the feasibility of the detection of episodes of rmd using contactless 3d video analysis and customised analysis software and b) the use of vestibular stimulation as a therapy for childhood rhythmic movement disorder.

Eligibility criteria:
inclusion criteria: * rmd diagnosis based on icsd iii criteria or rmd suspected * typically developing * child and accompanying adult are legally allowed to enter switzerland without a visa * both child and parent/legal guardian understand easy english or german exclusion criteria: * moderate or severe learning disability * neurological disorder (incl. autism, epilepsy, medicinally treated adhd) * currently using medication that influences sleep * known diseases of the vestibular system * self-reported sensitivity for motion sickness * body height \> 1.95 m (due to the constraints of the setup) * body weight \> 130 kg (due to the constraints of the setup) * flu, cold or other acute disease on study day that might influence measurements * pregnancy
a study evaluating the safety, tolerability, and pharmacokinetics of gdc-0425 administered with and without gemcitabine in patients with refractory solid tumors or lymphoma

Conditions: Solid Tumor

Summary: this is an open-label, multicenter, phase i, dose-escalation study to assess the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of gdc-0425 administered with and without gemcitabine.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * eastern cooperative oncology group (ecog) performance status of 0 - 1 * signed informed consent form * histologically or cytologically documented, locally advanced or metastatic solid tumors or lymphoma for which standard therapy either does not exist or has proven ineffective or intolerable * adequate hematologic and end-organ (liver and kidney) function * for female patients of childbearing potential and male patients with partners of childbearing potential, agreement by the patient that the patient and/or partner will use an effective form of contraception * patients enrolled in certain phases must be willing to provide fresh and/or archival tumor samples exclusion criteria: * history of prior significant toxicity from a same class of agents as gdc-0425 or gemcitabine requiring discontinuation of treatment * allergy, hypersensitivity or contraindication to the gdc-0425 formulation or gemcitabine * experimental therapy or anti-cancer therapy within 4 weeks prior to the first dose of study drug treatment * radiotherapy within 2 weeks prior to first dose of study drug treatment * more than two regimens of cytotoxic chemotherapy for the treatment of locally advanced or metastatic cancer * history of receiving high-dose chemotherapy requiring bone marrow or stem cell support * history of receiving radiation to more than 25% of bone marrow-bearing areas * acute drug-related toxicities from previous therapies have not resolved prior to study entry, except for alopecia and mild neuropathy * current severe, uncontrolled systemic disease (including but not limited to clinically significant cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding cancer * significant heart disease and heart dysfunction including but not limited to uncontrolled severe hypertension, heart failure, and reduced cardiac contractility * uncontrolled ascites, due to diseases other than cancer * inability or unwillingness to swallow pills/capsules * history of malabsorption or other condition that would interfere with drug absorption * any history of active stomach and/or intestine bleeding within the 6 months prior to screening * known hiv infection * pregnancy, lactation, or breastfeeding * known brain metastases that are untreated, symptomatic, or require therapy to control symptoms * inability to comply with study and follow up procedures

Keywords: solid cancers
iv paracetamol vs iv morphine vs placebo in sciatalgia

Conditions: Sciatica

Summary: siatalgia is one of the main symptoms related to emergency department presentations. patients with sciatalgia are seeking for immediate pain relief and little known regarding the pain management of these patients in emergency department. this study aim to trial the effect of intravenous paracetamol and morphine in patients presented with sciatalgia to emergency department.

siatalgia is one of the main symptoms related to emergency department presentations. patients with sciatalgia are seeking for immediate pain relief and little known regarding the pain management of these patients in emergency department. neuronal compression is the main cause of pain in sciatalgia rather than inflammation which also differ sciatalgia from the other type of pains in emergency department. sciatalgia is a kind of neuralgia and there is not so much option in the pain management of these patients. intravenous paracetamol and morphine is commonly used analgesics in various kind of pain in emergency department. so, this study aim to trial the effect of intravenous paracetamol and morphine in patients presented with sciatalgia to emergency department.

Eligibility criteria:
inclusion criteria: * patients with pain radiating to the sciatic nerve path * pain within the last one week * patients with positive straight leg raise * patients over 21 and lower than 65 years old exclusion criteria: * pain score lower than 40 mm in visual analogue scale score * neurological deficit * allergy to the study drugs * unstable vital signs * history of malignancy or rheumatological diseases or arthritis * history of chronic pain syndrome * receiving pain killer, steroid, anti-depressant, anti-convulsant and musculorelaxant within the last six hours. * drug or alcohol addiction * pregnancy or breast feeding * fewer more than 37.9 celsius degrees.

Keywords: sciatalgia emergency department paracetamol morphine